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Abstract
Background: Patient and public involvement (PPI) in clinical trials aims to ensure that research is carried out
collaboratively with patients and/or members of the public. However, current guidance on involving clinical
trial participants in PPI activities is not consistent.
Methods: We reviewed the concept of participant involvement, based on our experience. Two workshops
were held at the MRCCTU at UCL with the aim of defining participant involvement, considering its rationale;
benefits and challenges; and identifying appropriate models for participant involvement in clinical trials. We
considered how participant involvement might complement the involvement of other public contributors.
Both workshops were attended by two patient representatives and seven staff members with experience of
PPI in trials. Two of the staff members had also been involved in studies that had actively involved participants. They
shared details of that work to inform discussions.
Results: We defined trial participants as individuals taking part in the study in question, including those who had
already completed their trial treatment and/or follow-up. Because of their direct experience, involving participants may
offer advantages over other public contributors; for example, in studies of new interventions or procedures, and where
it is hard to identify or reach patient or community groups that include or speak for the study population.
Participant involvement is possible at all stages of a trial; however, because there are no participants to involve during the
design stage of a trial, prior to enrolment, participant involvement should complement and not replace involvement of
PPI stakeholders. A range of models, including those with managerial, oversight or responsive roles are appropriate for
involving participants; however, involvement in data safety and monitoring committees may not be appropriate where
there is a potential risk of unblinding.
Involvement of participants can improve the trial experience for other participants; optimising study procedures,
improving communications; however, there are some specific, notably, managing participant confidentiality and
practicalities relating to payments.
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Conclusions: Participant involvement in clinical trials is feasible and complements other forms of PPI in
clinical trials. Involving active participants offers significant advantages, particularly in circumstances where
trials are assessing new, or otherwise unavailable, therapies or processes. We recommend that current
guidance on PPI should be updated to routinely consider including participants as valid stakeholders in PPI
and potentially useful approach to PPI.
Background
Patient and public involvement (PPI) describes a variety
of activities that aim to ensure that trials are carried out
collaboratively with patients and/or members of the
public. There are a number of arguments to support PPI
in healthcare research, including clinical trials. For ex-
ample, there is a case that the public have a right to be
involved in publicly funded research that may impact on
their own health, or the services that they receive [1],
with many funding bodies now encouraging or insisting
upon some form of PPI in the trials that they fund. It
has also been argued that the experiences and personal
insights of patients, carers and service users can help to
improve research quality, relevance and impact [2]. On a
practical level, reports have implied that PPI improves
the overall quality of clinical trials and increases the like-
lihood that they will be completed successfully [3–6].
Despite evidence of increased PPI in health research,
including clinical trials, in recent years [7, 8], little is
published about involvement of trial participants. The
current INVOLVE definition (http://www.invo.org.uk/
find-out-more/what-is-public-involvement-in-research/)
of public involvement in health and social care research
excludes research participants from its classification of
members of the public. It states that for most studies, ‘it
is not appropriate for people involved in the research to
also be participants in the research as that can com-
promise both the researcher and the person involved,’
with the possible exceptions of participatory or action
research studies (http://www.invo.org.uk/posttypere-
source/how-to-find-people-to-involve/). In contrast,
other organisations have highlighted circumstances
when it may not only be possible, but also desirable, to
involve participants. For example, the UNAIDS Good
Participatory Practice (GPP) guidelines for biomedical
HIV-prevention trials [9] and similar guidance for tuber-
culosis (TB) trials [10], provide trialists with guidance on
how to involve a range of stakeholders, including trial
participants, in the design and conduct of clinical trials.
In a recent study of PPI in clinical trials conducted by
the Medical Research Council Clinical Trials Unit
(MRCCTU) at University College London (UCL), we
identified three studies that had actively involved partici-
pants [11] including two randomised controlled trials of
HIV prevention, set in the UK [12] and Africa [13], and
one cohort study of young people in the UK [14]. In the
two randomised trials, participants were actively in-
volved as collaborators or partners, offering advice to re-
searchers on the conduct of the studies, based on the
unique experiences and insights that participating in the
study offered. As we were unaware of any other reports
in the health literature relating to active involvement of
trial participants in PPI and because existing advice to
researchers about involving participants was conflicting,
we have explored participant involvement as a distinct
component of PPI activities in clinical trials. We aimed
to highlight inconsistencies between existing guidance
on participant involvement in PPI strategies for clinical
trials, to provide guidance and influence researchers to
give due consideration to this potentially novel aspect of
PPI for future trials.
Methods
The MRCCTU PPI Group is the Steering Committee re-
sponsible for developing, promoting and supporting the ac-
tive involvement of patients and the public in all clinical
studies that are being led by the MRCCTU. In August and
October 2015, nine members of the PPI steering group (in-
cluding two patient representatives, who work closely with
the MRCCTU and with other organisations, six MRCCTU
staff members, and an independent specialist advisor)
attended two discussion workshops on the active involve-
ment of participants. All the staff members have experience
of PPI in their research roles, either in clinical trials, cohort
studies or systematic reviews, and two of the staff members
had been directly involved in the three studies that had ac-
tively involved participants. The patient representatives had
been actively involved in PPI in various clinical trials and
other research, although neither had experience of being ac-
tively involved in PPI of trials in which they were also par-
ticipating. The workshops were chaired by the independent
specialist advisor.
During the discussion workshops, we focussed on
defining:
 Trial participants, as distinct from patients and
members of the public
 Active participant involvement
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 The rationale for involving participants
 When to involve participants in PPI
 How to involve participants in PPI
 Challenges specific to participant involvement
Although we aimed to reach consensus among commit-
tee members at the workshops on each of these topics,
given the small number of members and limited number
of trials in which participant involvement had been imple-
mented, this was intended to be exploratory and inform-
ative. No formal approach to reaching consensus (e.g. a
Delphi process) was undertaken, nor would it have been
appropriate. On each point of the workshop discussions
the chair facilitated discussions between the members and
recorded the agreed points. At the second workshop,
these were revisited and if needed and appropriate, re-
vised, such that the final report from the two workshops
was agreed by all members.
This paper summarises the findings of the workshops,
providing précis of participant involvement in two clinical
trials at the MRCCTU at UCL.
Results: workshop discussions and consensus
Defining trial participants
For the purposes of these discussions, we defined active
trial participants as an individual taking part in the trial in
question, irrespective of what stage the trial has reached.
We aimed to distinguish between these ‘active’ participants
and other potential PPI contributors (Table 1). For example,
‘active participants’ might include individuals who:
 Are still undergoing treatment or receiving an
investigational product as part of the trial
 Are still actively attending a clinic for scheduled
follow-up
 Are providing information to that study more
passively; for example, where follow-up information
is collected through a registry
 Have completed their own treatment or use of an
investigational product and follow-up while recruit-
ment of new participants to the trial is still
continuing
 Are ‘proxy participants’; for example, in trials
involving young children or infants, where parents
or care givers provide consent on behalf of their
child, the people providing consent are included in
our definition of participants
Individuals who had participated in a previous trial, or
who may participate in future trials were not considered to
be ‘active participants’ in this context and, while they may
still be involved in PPI activities as patient representatives
or members of the public, we did not consider this to be
participant involvement as we are describing here.
Defining active participant involvement
Our definition of active participant involvement is based
on INVOLVE’s broader definition of PPI. As such, we de-
fine active participant involvement in clinical trials as, ‘re-
search being carried out “with” or “by” trial participants,
rather than “to”, “about” or “for” them’. We consider in-
volvement of participants to be one form of PPI in which
trial participants are actively involved in contributing to
the conduct of the study. We do not believe that involving
participants should replace or preclude the involvement of
other public or patient contributors to research, but that
the approaches are complementary.
INVOLVE distinguishes between ‘involvement’ where
‘members of the public are actively involved in research
projects and in research organisation’; ‘engagement’ where
‘information and knowledge about research is provided and
disseminated’; and ‘participation’ where ‘people take part in
a research study’. Although active involvement of trial par-
ticipants requires both participation in, and engagement
with, the clinical trial, it is important to be clear that while
clinical trials regularly collect quantitative and qualitative
data on participants’ experiences in trials, such activities are
all examples of trial ‘participation’ and not ‘involvement’.
Table 2 aims to further clarify whether different ac-
tivities within clinical trials are classified as involve-
ment, engagement or participation, and further
examples of involvement activities are detailed in
Case study 1.
Table 1 Definitions of participants and other public contributors
Participant Patient/member
of the public
Someone who is a participant in this trial, even if they are no longer actively receiving
treatment or attending appointments
✓ X
Someone who is (or has been) a participant in another trial(s) or who may become a
participant in the future
X ✓
Someone who participated in a feasibility or pilot study that led to this trial X ✓
Someone who gave consent for an individual to participate in this trial, e.g. the parent of a child ✓ X
Carers, patients or people from organisations that represent patients, carers or other service users in this trial X ✓
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Case study 1. Participant involvement in practice: The
PROUD trial
PROUD was an open-label, wait-listed randomised controlled trial (RCT)
which evaluated oral pre-exposure prophylaxis (PrEP) as a HIV-
prevention option among gay men, other men who have
sex with men and trans women attending sexual health clinics in
England.
We developed an advertisement template on which to advertise
participant involvement meetings. We submitted the template to the
Ethics Committee for approval at the beginning of the trial and were
able to add details of the specific meetings as required. In
advance of a participant involvement meeting, the advertisement was
distributed to participants in the clinics (by hand and email), was posted
on the website which participants accessed to complete self-reported
data, and was distributed via a central trial mailing list that participants
could voluntarily sign up to. Participants who were interested in getting
involved with the advertised activity would contact the PPI coordinator
who would provide additional information.
We held participant involvement meetings in person, via teleconference
and WebEx, or linked regional in-person meetings via video-
conferencing facilities. Some topics were discussed in multiple meetings;
for example, the PROUD study results were discussed at four participant
involvement meetings in Brighton, London, Manchester and Sheffield.
We usually scheduled participant involvement meetings before
Community Engagement Group (the CEG was a more traditional PPI
advisory group) and Trial Steering Committee (TSC) meetings and
shared reports of the participant involvement meetings with the CEG
and TSC membership. PPI representatives on the TSC, CEG and Data
Safety Monitoring Committees (DSMC) were usually invited to facilitate
or attend the participant involvement meetings. In the interests of
transparency, we also posted the reports of the meetings on our
website (www.proud.mrc.ac.uk/patient_and_public_involvement).
In addition, we involved participants via email discussions; for example,
asking for their involvement to review a new ‘end of study’ case report
form (CRF) and review a new infographic explaining alternative
adherence regimens.
Defining the rationale for active participant involvement
Participants in a clinical trial have a direct and unique
experience of both the issue under investigation and of
taking part in the specific trial (Case study 2). As such,
they can offer an additional perspective to that of the other
public contributors. For example, their first-hand experi-
ence of the trial processes and procedures can be useful
when revising recruitment, retention or adherence strat-
egies. This may be particularly useful in trials of new inter-
ventions or procedures, where trial participants are the
only people with experience of the intervention or proced-
ure under investigation. Similarly, participant involvement
may be more valuable in trials where other models of PPI
might be difficult; for example, when it is hard to identify
or reach the trial population or where organisations that in-
clude or speak for the trial population do not exist. One ex-
ample may be a trial in people at risk of sexually
transmitted infections, as was the case in both the PROUD
and MDP301 trials.
Another potential advantage of involving participants
may be in advocating for the implementation of the trial
results. Patient representatives are regularly involved in
defining key messages and communicating study results.
In this context, trial participants can equally describe the
relevance and implications of the intervention. This can be
very powerful in communicating trial results and helping
people understand the human implications. Although
there may be trials in which involving participants may
not be necessary, feasible or desirable in all trials, due
consideration of whether and how participants might be
involved in the PPI strategy should be made at the
planning stages.
Case study 2. Rationale for participant involvement:
The MDP301 trial
The Microbicides Development Programme (MDP) 301 phase III,
randomised, double-blind, placebo-controlled clinical trial evaluated the
safety and effectiveness of a vaginal microbicide gel among HIV-
negative women in East and Southern Africa. We invited participants to
be involved in PPI activities throughout the life cycle of the trial.
Participants provided a unique perspective to PPI in this trial for a
number of reasons:
1. Participants had a unique experience of using a vaginal microbicide
gel as a novel HIV-prevention technology which was not available
outside of the trial
2. In an environment in which many formal structures were male
dominated and women’s voices were often hidden or drowned out by
socio-cultural norms of gender inequity, participant involvement
facilitated an opportunity to hear women’s voices as part of the PPI process.
Table 2 Examples of active participant involvement, other patient and public involvement, engagement and participation in clinical
trials
Activity Active participant
involvement
Patient/public
involvement
Public
engagement
Trial
participation
Patients, carers and/or family members take part in discussions to plan a trial X ✓ X X
Trial participants take part in a discussion about the recruitment strategy or the
development of a new questionnaire
✓ X X X
Trial participants take part in in-depth interviews about their experience of taking
part in the trial
X X X ✓
Representatives (e.g. staff, patients or family members) from a patient organisation
take part in a discussion about disseminating trial results
X ✓ X X
Trial participants complete questionnaires about how the trial is conducted X X X ✓
Results of the trial are presented to participants, patients and/or the public X X ✓ X
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(Continued)
It was difficult both to elicit input from women, and to involve women in a
discussion about a novel prevention technology in male-dominated spaces.
However, enrolment in the trial created safe spaces, in which women were
more able to provide input, and were eager to be involved with PPI activities
3. Participants were HIV-negative volunteers, representing a population
group that can be difficult to identify through other community sources
such as HIV support charities and support groups
4. HIV was a stigmatised topic within these communities and it was
especially difficult for married women to voice their opinions about the
need to protect themselves from HIV, but women found it more
acceptable to do so when in the exclusive company of other women
enrolled in a HIV-prevention trial
Defining when participants may be actively involved
PPI has a role throughout the life cycle of a clinical trial,
from identifying the research question to disseminating
the research results. The role of participant involvement
in the trial cycle mirrors other types of PPI at every
stage (Fig. 1), with the notable exception of prior to the
start of trial enrolment when there are no participants
enrolled in the trial. However, at each remaining stage,
participant involvement can have an additional or
complementary role to other PPI.
Defining how to actively involve participants
Participants can be invited to become involved with PPI
in a number of ways; for example, via existing trial
participant groups (for example, adherence support
groups), by forming specific participant involvement
groups, or by involving interested individuals directly.
The roles that participants may become involved in
within a trial may be managerial, oversight or responsive
roles [15], (Table 3). In our experience, while the
involvement of trial participants on managerial and
oversight committees is clearly defined, the concept of
trial participants’ involvement in responsive PPI models is
frequently confused with the concept of qualitative
research. As such, it is important to stress the distinction.
When involved in PPI, trial participants should be treated
in the same way as other patient and public contributors
and the questions posed to should be comparable. For
example, if a trial is experiencing problems with
recruitment, the trial team may arrange a PPI meeting, in
which the involved participants, patients and public
contributors work collaboratively with the researchers to
devise strategies to improve the situation. This is very
different from qualitative research, whereby a researcher
may interview participants about their experiences of trial
recruitment. The researcher then analyses the data and
produces findings. As two distinct approaches, participant
involvement does not replace the role of qualitative
research and vice versa.
Fig. 1 Participant involvement and patient and public involvement (PPI) at different stages of the clinical trial research cycle. A comparison of
opportunities for patient and public contributors and active trial participants involved in PPI throughout the trial cycle
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Using a range of PPI models to involve participants is
likely to increase involvement from a greater diversity of
participants. For example, some participants may prefer
long-term commitment to trial oversight committees while
others may prefer to be involved in responsive roles, such
as ad hoc, one-off meetings, or providing input on issues
or topics in which they are most interested (Case study 2).
There was only one PPI role identified as not being
appropriate for trial participants and that was active
involvement in DSMCs, particularly in blinded trials. This
was due to the likelihood of DSMC members being
unblinded and participants potentially finding out which
arm of the trial they are randomised to. Careful
consideration also needs to be given to participant
involvement in PPI activities that could risk data
contamination (e.g. where participants believe that they
know what arm they are in) or exposure of hidden
randomisations (such as in a Zelen design [16], where
randomisation, but not the intervention, takes place prior
to consent being agreed). In the latter example, instead of
prohibiting participant involvement in PPI it may be a case
of deferring participant involvement until after the
occurrence of the hidden randomisation.
Defining challenges of actively involving participants in
PPI in clinical trials
As with other types of PPI, there are a number of
challenges to involving participants that need to be
considered; for example, considering that people with a
disease or condition may become too sick to remain
involved or that specific training or support for participants
to become involved constructively may be needed. As for
all PPI, trialists should consider additional requirements
that actively involving participants may require and plan
for this appropriately in terms of trial budget and
resources. Similarly, as with other forms of PPI, the
representativeness of the contributors may be called into
question; therefore, it is important to be clear that the goal
is to seek a broad range of perspectives rather than trying to
gain representativeness of the population groups (http://
www.invo.org.uk/posttyperesource/how-to-find-people-to-
involve/).
There are some challenges that are unique to involving
participants (Case study 3). One key challenge relates to
participant confidentiality, and how best to manage that
confidentiality in the context of needing to store personal
information (names and contact details) in order to
facilitate involvement. Related to this is the practical issue
of paying or reimbursing participants for their time and
travel costs, in line with other PPI stakeholders. This can
potentially cause conflict between respecting confidentiality
of trial participants and holding personal details in order to
facilitate payments, but there is also the danger of creating
the impression that the involved participants are being
‘paid’ (or receiving special consideration) and others not.
There are also specific challenges around confidentiality
where the populations involved may be susceptible to being
stigmatised or discriminated against. Another challenge
Table 3 Potential models of participant involvement in trials
Role Model Appropriate for
participant
involvement?
Comments
Managerial Patient/public representative on Trial
Management Group
Yes Thought should be given to how to recruit and train participants who
might be involved in a TMG – they need an understanding of research
and to be confident and articulate in this type of setting
Oversight Patient and participant research
partners
Yes A committee made up of participants and patients with an oversight
remit and clear reporting route into TMG and/or TSC
Patient/public representative on Trial
Steering Committee
Yes – but with
caveats
Should not be voting members as not independent of the trial
Patient/public representative on Data
Safety Monitoring Committee
No Involvement not appropriate because of danger of un-blinding and of
bias Information from an advisory group (e.g. patient and participant re-
search partners) could be considered by a DSMC
Responsive Involvement on specific tasks (e.g.
facilitated through existing patient
groups)
Yes Participants involved in specific tasks, either on a one-off or ongoing basis.
For example, participants help to design interview schedules, draft key
messages of trial results, be advocates for the trial findings, etc.
Ad hoc participant meetings Yes Participant meetings to discuss topics and issues as they arise. For
example, ways to address slow accrual, ways to respond to negative
rumours, etc.
Ongoing participant groups Yes Regular meetings of participants to provide feedback and actions to
trialists on a regular basis
Community advisory groups Yes Participants contribute via membership of a community advisory group
for the ongoing trial
Community meetings to advise trial
teams
Yes Participants contribute via community meetings held to advise the
ongoing trial
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specific to the involvement of participants from a research
design perspective is the risk of ‘involvement’ undermining
blinding procedures or contamination between arms. Risks
to the trial design need to be considered when deciding
whether to involve participants in PPI and when choosing
which models of involvement to employ.
An additional challenge specific to involving
participants is that while PPI activities do not require
ethical approval or consent from stakeholders, because
participant involvement is still a new approach, it may be
necessary to discuss requirements directly with ethics
committees, making a clear distinction between materials
inviting participants to take part in PPI and recruitment
material for the trial to avoid potential confusion.
There are also specific challenges of involving
participants from different populations in different
contexts; for example, involving participants in countries
with no tradition of PPI or with no culture of
challenging medical advice, and involving participants
who live distant to the research centres or who cannot
easily travel to where the trial is being conducted.
However, there are a range of alternative options to
overcome some of these challenges, such as partnering
participants with other PPI stakeholders and/or
facilitating remote involvement instead of face-to-face
meetings for example. However, these factors should
only affect decisions on how to involve participants ra-
ther than whether to involve them.
Case study 3. Challenges of participant involvement:
experiences from the PROUD trial
In PROUD, the main challenges related to managing participant
involvement within a clinical trial unit whose expectations are that
trialists will not have direct contact with participants. As such, it was
challenging setting up systems to hold participants’ email addresses,
setting up the mailing list, and even registering participants by name for
meeting attendance at the CTU offices. We overcame these challenges
by largely managing direct email contact between the participants and
the PPI coordinator via a secure and dedicated NHS email account,
finding a secure one-way distribution mailing list, and creating a way to
register participants by numbers instead of names for the meetings
(proud1, proud2, etc.).
There were challenges in explaining participant involvement to other
researchers and PPI stakeholders, and in distinguishing participant
involvement from participation in qualitative research or participant
engagement activities. However, there were no problems in explaining
participant involvement to trial participants.
The Ethics Committee wanted to approve the template advertisement
for meetings, but then agreed that the involvement processes were
equivalent to other PPI activities and did not require additional ethics
review.
PROUD was an open-label trial in which 50% of participants were not
given any product for the first year of follow-up. The Trial Management
Group discussed restricting participant involvement meetings to online
or telephone meetings or holding separate meetings with participants
in the active and control groups in order to avoid participants meeting
and potentially sharing products. However, we already knew that partici
pants could meet each other at the research clinics, we encouraged
snowball recruitment, and our baseline data suggested social and sexual
(Continued)
networking within the cohort. Consequently, we decided that face-to-
face participant involvement meetings did not substantially increase the
risk of contamination. However, the circumstances of each trial are dif
ferent and research teams need to consider which PPI models best suit
the purposes of their specific trials to avoid introducing risks to the trial
design.
Discussion
Active involvement of participants in PPI can benefit the
delivery of clinical trials by bettering the trial experience
for current and future trial participants, optimising
study procedures, and improving communication of key
messages and results. Participant involvement may
complement other PPI activities relating to clinical trials,
recognising the unique perspective of participants as one
of a number of key stakeholders in PPI processes.
In the trials we have considered, we have demonstrated
that including trial participants in PPI can add unique
insight and input into the running of a trial in which they
are participating. This may be particularly valuable in
trials where the participants are not otherwise organised
into established groups (for example, in prevention trials),
or where there are cultural or societal barriers to more
traditional PPI roles. It may also be valuable in trials of
novel treatments in which trial participants are the first or
only stakeholder with experience of the treatment.
However, because this approach is novel to many
researchers and PPI stakeholders, a number of challenges
and some practicalities, as discussed here, need to be
thoroughly considered.
Clearly, there are limitations of this work. As this is a
novel and emerging approach, we are aware of only two
clinical trials at the MRCCTU in which participants
have actively contributed to PPI, although in line with
the UNAIDS GPP guidelines this is common practice in
HIV-prevention trials conducted globally. Our discus-
sions were, therefore, greatly influenced by the limited
sample in which there was a largely positive experience
of participant involvement. We also acknowledge that
we did not undertake a formal consensus-gathering ap-
proach as it would not have been appropriate in this
context. That said, the authors represent a range of per-
spectives including researchers, with and without direct
experiences of participant involvement, but all with ex-
perience in PPI, and from patient and public contribu-
tors with extensive clinical trial experience. All agreed
on certain advantages of involving participants. We are
not suggesting that all trials must have participant in-
volvement, or that this type of involvement should re-
place the need for involvement of other PPI
stakeholders. We see the approaches as complementary.
There may well be trial scenarios that we have not
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considered where participant involvement would be un-
likely to add extra benefits to PPI.
We aim to continue to evaluate the role of participants
in PPI and to explore appropriate models to enhance their
involvement. We are, therefore, conducting a formal
evaluation of the experiences of participants and
researchers in the PROUD study which we hope will add
further weight to the narrative presented here on
participant involvement as this field continues to emerge.
Conclusions
The continuing evolution and development of PPI in
clinical trials should include actively involving
participants. We recommend that trialists and trials
units give due consideration to actively involving trial
participants in their trials, in particular where
interventions under investigation are novel and where
an obvious patient group is not well established. We also
recommend that organisations such as INVOLVE
reconsider their definitions of PPI stakeholders to ensure
that trial participants are included within their remit.
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